"is it fair to say that rvx would  keep the new targets for themselves... or would they want to hold off a sale till they start the new trial and raise expectations .. or is it not worth pursuing as Apabetalone would not be near as effective???"

I think it is fair to say that there are MANY paths forward for apabetalone and the remainder of the pre-clinical compound library. I have no idea what kind of discussions are going on in regards to trials, indications, other molecules, licensing, partnerships, sale of apbetalone, sale of the company, etc., etc. Many paths forward.

BDAZ